主胰管型IPMN外科管理:国际专家调查与病例情景研究
该研究对221名国际专家进行在线调查(含病例情景),回收97份(44%)。对于全胰腺胰管扩张(>5 mm)的主胰管/混合型IPMN患者,41%建议每3-6个月非手术监测,59%建议手术;手术者中46%选择全胰切除、31%选择胰十二指肠切除加随访。专家间治疗策略缺乏共识。
要点
- 主胰管/混合型IPMN全胰腺胰管扩张(>5 mm)时,41%专家建议监测,59%建议手术。
- 建议手术的专家中,46%选择全胰切除,31%选择胰十二指肠切除加随访。
- 外科与消化科专家、不同洲及经验年限间建议无结构差异。
核心结论
- 国际调查显示主胰管/混合型IPMN治疗策略在专家间存在临床相关的不共识。
- 需开展包含部分与全胰切除后生活质量的长期随访研究。
研究设计与样本
- 在线调查含病例情景,发送给221名过去十年发表过主胰管/混合型IPMN相关研究的国际专家及欧洲研究组和国际胰腺病学会胰腺囊肿指南委员会成员。
- 共97名专家(67名外科医生,30名消化科医生)来自19个国家回复,回复率44%。
主要发现
- 93%的回复者工作在学术医院,治疗IPMN的中位经验为15年。
- 全胰腺胰管扩张(>5 mm)的主胰管/混合型IPMN患者中,41%(n=37)建议每3-6个月非手术监测,59%(n=54)建议手术干预。
- 建议手术者中,46%(n=25)选择全胰切除,31%(n=17)选择胰十二指肠切除加随访。
- 外科医生与消化科医生之间、不同洲回复者之间及基于经验年限的建议无结构差异。
关键数值与推荐
- 主胰管/混合型IPMN切除标本浸润癌风险为33%-60%。
- 多数指南建议手术适合的患者切除主胰管型和混合型IPMN,但手术策略(部分或全胰切除)建议不同。
临床怎么用
- 对于全胰腺胰管扩张(>5 mm)的主胰管/混合型IPMN,专家意见分歧明显,临床决策需个体化。
- 部分专家支持非手术监测(每3-6个月),部分支持手术,手术方式全胰切除与胰十二指肠切除加随访均有支持。
局限性
- 回复率44%,可能存在无应答偏倚。
- 调查基于病例情景,非真实临床决策。
- 专家意见不代表长期结局证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of invasive cancer in resected intraductal papillary mucinous neoplasm with main pancreatic duct involvement is 33%-60%. Most guidelines, therefore, advise resection of main duct intraductal papillary mucinous neoplasm and mixed type intraductal papillary mucinous neoplasm in surgically fit patients, although advice on the surgical strategy (partial or total pancreatectomy) differs. We performed a survey amongst international experts to guide the design of future studies and help to prepare for a single international set of guidelines. METHODS: An online survey including case vignettes was sent to 221 international experts who had published on main duct/mixed type intraductal papillary mucinous neoplasm in the previous decade and to all surgeon and gastroenterologist members of the pancreatic cyst guideline committees of the European Study Group and the International Association of Pancreatology. RESULTS: Overall, 97 experts (67 surgeons, 30 gastroenterologists) from 19 countries replied (44% response rate). Most (93%) worked in an academic hospital, with a median of 15 years' experience with intraductal papillary mucinous neoplasm treatment. In main duct/mixed type intraductal papillary mucinous neoplasm patients with pancreatic duct dilation (>5 mm) in the entire pancreas, 41% (n = 37) advised nonoperative surveillance every 3-6 months, whereas 59% (n = 54) advised operative intervention. Of those who advised operative intervention, 46% (n = 25) would perform a total pancreatectomy and 31% (n = 17) pancreatoduodenectomy with follow-up. No structural differences in advice were seen between surgeons and gastroenterologists, between continents where the respondents lived, and based on years of experience. CONCLUSION: This international survey identified a clinically relevant lack of consensus in the treatment strategy in main duct/mixed type intraductal papillary mucinous neoplasm among experts. Studies with long-term follow-up including quality of life after partial and total pancreatectomy for main duct/mixed type intraductal papillary mucinous neoplasm are required.
引用
- Scholten L, van Huijgevoort NCM, Bruno MJ, et al. Surgical management of intraductal papillary mucinous neoplasm with main duct involvement: an international expert survey and case-vignette study. Surgery. 2018. PMID: 29778250. doi:10.1016/j.surg.2018.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。